CEO's use of Eli Lilly's (LLY) weight loss drug Mounjaro over Novo Nordisk's (NVO) rival product, Ozempic. Read more here.

A visual look at Wall Street's Santa Claus rallies since 2000, even as such a rally comes under pressure on Thursday. Read ...

Small Cap Opportunity Fund A Shares posted a return of 5.25% in the third quarter of 2024. As we were reminded in August and ...

While financial assets generally were strong in the third quarter, volatility trended higher as markets continued to be ...

Gap is on the rise, with strong Q3 results signaling a turnaround. It trades at just 11.9x fwd P/E, well below the industry ...

Trainline is capitalizing on the digitization of rail travel with a 17% sales increase. See why we recommend a buy rating on ...

Nokian grew underlying earnings regardless prior to the rapid production ramp-up. Its Romanian factory will start production ...

Mueller Water Products is a strong long-term investment with its innovative water products, strong financial performance, and ...

Leggett & Platt's vertical integration and restructuring plans are expected to enhance operating margins and free cash flow ...

Green Brick's Q3 2024 revenues were $523 million, which is a 25.7% increase YoY. It offers the possibility of buying a solid ...

Melco Resorts' Q324 shows improvement. Substantial debt and upcoming maturities pose significant financial risks. Read an ...

TFLO is a top choice for reliable income investing, offering stability and above-average yields in uncertain market ...